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Abstract: Objectives: Evaluate cardiovascular risk factors in Portuguese obese children and adolescents and the long-term 
effects of lifestyle modifications on such risk factors. 
Design: Transversal cohort study and longitudinal study.  
Setting: University Hospital S. João and Children’s Hospital Maria Pia, Porto.  
Patients/Participants: 148 obese children and adolescents [81 females (54.7%); mean age of 11.0 years] and 33 controls 
(sex and age matched) participated in a cross-sectional study. Sixty obese patients agreed to participate in an one year 
longitudinal study after medical and nutritionist appointments to improve lifestyle modification; a substantial body mass 
index (BMI) reduction was defined by a decrease in BMI z-score (BMI z-sc) of 0.3 or more over the studied period. 
Main Outcome measures: Lipid profile (triglycerides, cholesterol, HDLc, LDLc, lipoprotein (a), apolipoproteins A and B) 
and circulating levels of C-reactive protein (CRP), adiponectin, glucose, and insulin.  
Results: Compared with the lean children, obese patients demonstrated statistically significantly higher insulin resistance 
index  [Homeostasis  model  assessment  (HOMA)],  and  triglycerides,  LDLc,  apolipoprotein  (apo)  B,  insulin  and  CRP 
concentrations, whereas their HDLc and apo A levels were significantly lower (cross-sectional study). In the longitudinal 
study (n=60), a substantial BMI reduction occurred in 17 (28.3%) obese patients which led to a significant reduction in 
triglycerides, cholesterol, LDLc, apo B, glucose and insulin levels and in HOMA. The  BMI values over the studied 
period correlated inversely and significantly with BMI (P<0.001) and HOMA (P=0.026) values observed at baseline. In 
multiple linear regression analysis, BMI at baseline remained associated to changes in BMI over the studied period 
(standardised Beta: -0.271, P=0.05). 
Conclusion: Our data demonstrates that small reductions in BMI-zc, imposed by lifestyle modifications in obese children 
and adolescents, improve the cardiovascular risk profile of such patients. Furthermore, patients with higher BMI and/or 
insulin resistance seem to experience a greater relative reduction in their BMI after lifestyle improvements. 
Keywords: Lipid profile, insulin resistance, inflammation, childhood obesity, lifestyle modifications. 
1. INTRODUCTION 
  Obesity is increasing all over the world both in developed 
and  underdeveloped  countries  [1,  2]  and  is  known  to  be  
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associated with inflammatory changes, insulin resistance and 
with  a  hyperlipidemic  state  [3].  The  adipocyte  is  an 
important source of cytokines, namely plasminogen activator 
inhibitor type 1 (PAI)-1, leptin, interleukin (IL)-6 and tumor 
necrosis factor (TNF)-alpha, and their levels are significantly 
higher in the plasma of obese patients [4]. Moreover, some 
inflammatory  markers,  such  as  C-reactive  protein  (CRP), 44    The Open Biochemistry Journal, 2012, Volume 6  Nascimento et al. 
show  an  independent  positive  association  with  body  mass 
index (BMI) [5]. 
  Cardiovascular  (CV)  morbidity  and  mortality  is 
associated with the classic risk factors, namely dyslipidemia, 
hypertension  and  impaired  glucose  metabolism.  However, 
more recently, inflammatory mechanisms were recognized as 
playing  a  vital  role  in  initiation,  maintenance  and 
progression  of  atherosclerotic  vascular  disease. 
Atherosclerosis  is  an  inflammatory  disease  with  the 
participation  of  leukocytes  and  several  cytokines.  Among 
several  inflammatory  markers  that  have  been  shown  to 
predict CV events [namely IL-6, tumor necrosis factor-alpha 
and soluble intercellular adhesion molecule (ICAM)-1] CRP 
levels have emerged as the most powerful marker [6]. 
  Regular  physical  activity  is  known  to  reduce  obesity-
related markers and risk of type 2 diabetes (physical activity 
is  associated  with  improved  insulin  sensitivity)  and  to 
improve  endothelial  function,  lipid  profile  (e.g.,  exercise 
decreases  plasma  triglycerides  (TG)  and  increases  high 
density  lipoprotein  (HDL),  as  well  as  several  oxidative 
stress/inflammatory markers, all risk factors for CV disease 
(CVD) [7-10]. Diet restriction per se may reduce fat mass, 
total  cholesterol  (Chol)  and  low  density  lipoprotein 
cholesterol  (LDLc)  without  apparent  effect  in  HDL  and 
limited effect on insulin resistance. The effect of both diet 
and  physical  exercise  in  obese  individuals  appear  to  be 
additive  with  greater  impact  in  the  improvement  of  lipid 
profile and insulin resistance [11]. However, few data exists 
in  literature  regarding  the  long-term  effects  of  physical 
activity on young obese subjects. Moreover, in most studies, 
children obey to a restricted physical exercise program or a 
food  intake  program,  but  the  effect  of  “natural”  lifestyle 
modifications on CV risk factors has been poorly explored 
[12-14].  
  Higher  cardiorespiratory  fitness  (CRF)  has  been 
associated  to  a  decrease  in  CVD  risk  markers,  CVD 
morbidity and mortality [15]. Besides physical activity, the 
initial CRF of an individual appears to be an independent 
predictor  of  weight  variation.  Individuals  with  lower  CRF 
are more prone to gain weight when compared to those with 
higher CRF [16]. Actually, children with lower CRF usually 
present diminished levels of physical activity and increased 
time expended in sedentary behaviours. Despite the strong 
genetic  influence,  CRF  status  can  be  modulated  through 
physical  activity,  which  is  a  main  determinant  of  CRF  in 
pediatric populations [17]. 
  The  physical  activity  performed  by  children  and 
adolescents in southern European countries is lower than in 
countries  from  centre  and  northern  Europe.  This  fact  may 
explain  the  geographical  differences  in  obese  prevalence 
found in Europe [17]. In fact, recent studies showed a very 
high  prevalence  of  overweight/obesity  (about  30%)  in 
Portuguese  children  when  compared  to  other  European 
countries [18, 19]. Thus, the study of obesity is of particular 
importance in our country.  
  The  aim  of  this  study  was  to  evaluate  the  short-term 
effects of lifestyle modifications, through a decrease in body 
mass  index  z-score  (BMI  z-sc),  on  CV  risk  factors 
(circulating levels of C-reactive protein, glucose, insulin and 
lipid profile), in Portuguese obese children and adolescents. 
2. MATERIAL AND METHODS 
2.1. Subjects 
  The protocol used for all participants was approved by 
the Committees on Ethics of the University Hospital S. João 
and  of  the  Children’s  Hospital  Maria  Pia,  Porto.  Obese 
children  and  adolescents,  aged  5-18  years,  were  identified 
from medical records, at the Departments of Pediatrics of the 
referred hospitals.  
  Obesity  was  defined  as  BMI  greater  than  the  95
th 
percentile for age and gender, according to 2000 Centers for 
Disease  Control  and  Prevention  (CDC)  growth  charts. 
Because BMI is not normally distributed and not adjusted for 
sex and age we used BMI z-sc. 
  One hundred and forty eight (n=148) obese children and 
adolescents  participated  in  the  study  after  informed  and 
written  consent  from  their  parents.  Thirty  three  healthy 
control subjects, age and sex matched with obese patients, 
were recruited from the general population. The BMIs of the 
controls were lower than the 85
th percentile adjusted for sex 
and age. Obese patients were evaluated at the beginning of 
the study and compared with controls (cross-sectional study).  
  All obese individuals (n=148) were motivated to change 
their  lifestyle  habits  (conventional  weight  loss  programs 
based on dietary counseling and encouragement to exercise), 
but only sixty patients agreed to participate in a longitudinal 
study (one year of follow up). A substantial BMI reduction 
was defined by a decrease in BMI z-sc of 0.3 or more over 
the studied period. One year after the beginning of lifestyle 
modification  intervention,  obese  children/adolescents  were 
classified as: 1) those who have achieved a substantial BMI 
reduction or 2) those who have not achieved a substantial 
BMI  reduction.  In  the  longitudinal  study,  clinical  and 
biochemical data were obtained at the beginning as well as at 
the conclusion, after one year of follow-up. 
  Criteria  of  exclusion  were:  smokers,  subjects  under 
regular medication or with diabetes mellitus, endocrinologic 
disorders,  and  hereditary,  inflammatory  or  infectious 
diseases. 
2.2. Procedures and Assays 
2.2.1. Clinical Examination 
  The participants were invited to the research centers after 
an  overnight  fast  and  clinical  data  regarding  the  sample 
population was collected. The development of puberty was 
clinically  assessed  on  the  basis  of  Tanner  stages.  The 
physical  examination  included  the  measurement  of  height, 
weight  and  the  observation  of  the  presence  of  cutaneous 
markers related with obesity and its comorbidity. 
2.2.2. Blood Samples 
  Blood  samples  were  obtained  on  a  fasting  basis  and 
processed  within  2h  of  collection.  Blood  was  obtained  by 
venipuncture in ethylenediaminetetraacetic acid (EDTA) 
containing  tubes.  Plasma  aliquots  were  made  and 
immediately stored at - 70
oC until assayed. 
2.2.3. Laboratory Analysis 
  The  determination  of  circulating  levels  of  glucose, 
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routine automated technology (Glucose, Insulin, Cholesterol, 
Triglycerides,  HDL  Cholesterol  Direct,  LDL  Cholesterol 
Direct,  Apolipoprotein  (apo)  A1  and  apo  B,  ABX 
Diagnostics). Lipoprotein (a) ((Lp(a)) plasma concentration 
was determinated by an immunoturbidimetric method. 
  Homeostasis model assessment (HOMA), used to detect 
the degree of insulin resistance [20], was calculated by using 
the following formula: resistance (HOMA) = (fasting insulin 
(µU/mL)   fasting glucose (mmol/L)/22.5).  
  Plasma  levels  of  CRP  were  evaluated  by 
immunoturbidimetry  [CRP  (latex)  High-Sensitivity,  Roche 
Diagnostics]. 
  Plasma  concentration  of  adiponectin  was  evaluated  by 
using  a  standard  commercial  enzyme-linked  immunoassay 
(Adiponectin, R&D Systems). 
2.3. Statistical Analysis 
  Statistical  analysis  was  performed  using  the  Statistical 
Package  for  Social  Sciences  (SPSS,  version  17.0)  for 
Windows. Kolmogorov-Smirnov analysis was used to test if 
the  results  were  normally  distributed.  Results  with  normal 
distribution  were  presented  as  mean  ±  standard  deviation, 
whilst  irregular  distributions  were  presented  as  median 
(interquartile range).  
  To compare obese and control groups, Student’s unpaired 
t-test  was  used  for  parameters  presenting  a  Gaussian 
distribution and the Mann-Whitney U-test in the case of a 
non-Gaussian  distribution.  To  evaluate  the  differences 
occurring along the longitudinal study, we used the paired 
Student  t  test  for  parametric  and  Wilcoxon  Signed  Ranks 
Test for non-parametric variables. 
  Spearman’s  rank  correlation  coefficient  was  used  to 
evaluate relationships between sets of data.  
  To evaluate the contribution of the different variables to 
BMI  reduction  over  the  studied  period,  we  performed 
multiple regression analysis, using stepwise selection with an 
entry  criteria  of  P  <0.05,  after  log  transformation  of  the 
variables (when necessary). 
  Significance was accepted at P less than 0.05. 
3. RESULTS 
  The  characteristics  of  the  participants  in  the  cross-
sectional study are presented in Table 1. Obese patients and 
controls were matched for age and gender. Compared with 
the lean children, obese patients demonstrated significantly 
higher insulin resistance index (HOMA), and TG, LDLc, apo 
B, insulin and CRP concentrations, whereas their HDLc and 
apo  A  levels  were  significantly  lower  (Table  2).  The 
participants  in  the  cross-sectional  study  had  BMI  which 
correlated positively and significantly to TG (r = 0.300, P < 
0.001), LDLc (r = 0.235, P = 0.001), insulin (r = 0.652, P < 
0.001), HOMA (r = 0.646, P < 0.001), and CRP (r = 0.451, 
P < 0.001) values, and negatively with HDLc (r = -0.462, P 
<  0.001).  Adiponectin  levels  (n=153)  correlated  inversely 
and significantly with age (r = -0.299, P < 0.001), BMI (r = -
0.220,  P  =  0.006),  TG  (r  =  -0.390,  P  <  0.001)  and  total 
cholesterol/HDLc (Chol/HDLc) ratio (r = -0.270, P = 0.001), 
insulin (r = -0.211, P = 0.009) and HOMA (r = -0.223, P = 
0.006), and correlated positively and significantly with apo 
A (r = 0.214, P = 0.008) and HDLc (r = 0.270, P = 0.001).  
  Sixty obese patients participated in the longitudinal study 
and,  after  one  year  of  follow  up,  17  (28.3%)  achieved  a 
substantial BMI z-sc reduction (mean  BMI z-sc = -0.46 ± 
0.16), while 43 individuals did not reach the cut-off value 
(mean  BMI z-sc = 0.01 ± 0.26) (Table 3). At baseline (T1), 
no significant differences were observed in age, sex, BMI, 
BMI z-sc, and in any markers of the metabolic syndrome or 
inflammatory  markers  between  obese  children  who 
presented with and without substantial BMI z-sc reduction, 
at the end of the study (T2). 
  A substantial decrease in BMI z-sc in 17 children led to a 
significant  reduction  in  TG,  cholesterol,  LDLc,  apo  B, 
glucose, insulin levels and in HOMA (Table 4). In the 43 
children  without  change  of  BMI  z-sc,  a  reduction  in 
adiponectin  and  in  glucose  values  occurred  as  well  as  a 
significantly increase in Lp(a) values (Table 4). 
  The  BMI values over the studied period (longitudinal 
study, n=60) correlated inversely and significantly with BMI 
at baseline (r = -0.487, P<0.001, Fig. 1A), and HOMA at 
baseline (r = -0.291, P=0.026, Fig. 1B). In multiple linear 
regression  analysis,  BMI  values  at  baseline  remained 
associated  to  changes  in  BMI  over  the  studied  period 
(standardised Beta: -0.271, P=0.05). 
4. DISCUSSION 
  The  present  study  was  able  to  demonstrate  in  young 
obese  patients  that  small  reductions  in  BMI  z-sc  are 
associated with significant improvements in lipid profile and 
in insulin resistance index.  
Table 1.  Characteristics of the Participants in the Cross-Sectional Study 
  Controls (n=33)  Obese (n=148)  p 
Age (years)  10.2 ± 3.6  11.0 ± 3.0  0.173 
Sex (female)  20 (60,6%)  81 (54,7%)  0.852 
Weight (kg)  34.7 ± 12.8  69.0 ± 22.8  <0.001 
BMI (kg/m )  17.4 ± 2.2  29.8 ± 5.4  <0.001 
BMI z-score  0.09 ± 0.68  2.30 ± 0.44  <0.001 
BMI, body mass index. 
Values are given as mean ± SD, unless otherwise indicated. 46    The Open Biochemistry Journal, 2012, Volume 6  Nascimento et al. 
Table 2.  Biochemical Data of the Participants in the Cross-Sectional Study 
   Controls (n=33)  Obese (n=148)  p 
Lipid profile 
TG (mmol/l)  0.72 (0.57-0.85)  0.86 (0.60-1.25)  0.017 
Chol (mmol/l)  4.29 (3.82-4.81)  4.11 (3.68-4.60)  0.241 
HDLc (mmol/l)  1.25 (1.12-1.33)  1.09 (0.92-1.24)  <0.001 
LDLc (mmol/l)  2.31 (1.85-2.65)  2.63 (2.20-3.10)  0.001 
Lpa (mg/dl)  28.6 (18.1-50.3)  25.8 (10.6-46.5)  0.194 
Apo A (mg/dl)  132.5 ± 9.7  118.5 ± 18.2  <0.001 
Apo B (mg/dl)  73.8 ± 15.8  81.3 ± 20.3  0.042 
Chol/HDLc  3.53 (3.12-3.91)  3.86 (3.26-4.56)  0.017 
Apo A/Apo B  1.89 ± 0.50  1.53 ± 0.41  <0.001 
Glucose metabolism 
Glucose (mmol/l)  4.90 (4.68-5.17)  5.00 (4.80-5.20)  0.174 
Insulin (mmol/l)  5.28 (4.11-6.82)  12.95 (8.92-18.88)  <0.001 
HOMA  1.14 (0.84-1.47)  2.90 (1.94-4.24)  <0.001 
Inflammatoy markers 
Adiponectin (mg/l)  7.83 (5.15-10.01)*  7.99 (5.19-11.12)**  0.884 
CRP (mg/l)  0.25 (0.18-0.68)  1.64 (0.80-3.66)   <0.001 
*, n=14; **, n=139 ; Values are given as mean ± SD or median (interquartile range). 
TG, triglycerides; Chol, cholesterol; HDLc, High Density Lipoprotein cholesterol; LDLc, Low Density Lipoprotein cholesterol; Lp(a), lipoprotein (a); apo, apolipoprotein; HOMA, 
Homeostasis Model Assessment (insulin resistance index); CRP, C-reactive protein. 
 
Table 3. Characteristics of the Participants in the Longitudinal Study (One Year of Follow-Up) 
  BMI z-sc < 0,3 (n=43)      BMI z-sc   0,3 (n=17)   
  T1  T2  p  T1  T2  p 
Age (years)  11.5 ± 2.21  12.6 ± 2.2  <0.001  11.5 ± 3.0  12.6 ± 3.0  <0.001 
Weight (kg)  70.2 ± 19.1  78.0 ± 18.0  <0.001  69.9 ± 16.7  67.5 ± 13.4  0.191 
Waist/Hip  0.928 ± 0.054  0.920 ± 0.065  0.347  0.912 ± 0.028  0.905 ± 0.059  0.630 
Waist/Height  0.609 ± 0.059  0.616 ± 0.058  0.354  0.628 ± 0.045  0.569 ± 0.057  <0.001 
BMI (kg/m )  29.2 ± 4.8  30.6 ± 4.8  0.005  30.2 ± 4.0  27.1 ± 3.1  <0.001 
BMI z-score  2.14 ± 0.36  2.15 ± 0.32  0.845  2.36 ± 0.68  1.90 ± 0.65  <0.001 
BMI, body mass index Values are given as mean ± SD. 
  In  a  first  analysis  (cross-sectional  study)  we  compared 
obese  patients  with  a  lean  control  group.  As  some  of  the 
studied CV risk factors change with age and are influenced 
by gender, we matched controls and patients for gender and 
age. The results obtained confirm obesity as an inflammatory 
disease.  Indeed,  the  median  CRP  value  observed  in  obese 
children and adolescents was about 6 times higher than that 
observed in controls, demonstrating an inflammatory process 
in  such  young  patients  (Table 2 ).  We  also  observed  that 
obese  patients  presented  with  an  altered  lipid  profile  and 
raised  markers  of  insulin  resistance  when  compared  with 
controls (Table 2). 
  There are few studies assessing the long-term changes of 
lifestyle  modifications  in  obese  children  and  adolescents, 
particularly on CV risk factors. In the present longitudinal 
study, obese patients (children and adolescents) were asked 
to  improve  their  lifestyle  habits  (conventional  weight  loss 
programs based on dietary counselling and encouragement to Cardiovascular Risk Factors in Portuguese Obese Children and Adolescents  The Open Biochemistry Journal, 2012, Volume 6    47 
Table 4.  Biochemical Data of the Participants in the Longitudinal Study (One Year of Follow-Up) 
  BMI z-sc < 0,3 (n=43)    BMI z-sc   0,3 (n=17) 
  T1  T2  p  T1  T2  p 
Lipid profile 
TG (mmol/l)  0.77 (0.50-1.02)  0.65 (0.51-0.95)  0.795  0.87 (0.64-1.30)  0.63 (0.50-0.90)  0.003 
Chol (mmol/l)  3.93 (3.50-4.68)  4.10 (3.51-4.50)  0.929  4.24 (3.80-4.70)  4.00 (3.58-4.24)  0.009 
HDLc (mmol/l)  1.14 (0.98-1.32)  1.13 (0.93-1.31)  0.960  1.13 (0.98-1.26)  1.17 (0.92-1.32)  0.819 
LDLc (mmol/l)  2.59 (2.20-3.00)  2.47 (2.21-2.90)  0.534  2.69 (2.30-3.24)  2.42 (2.06-2.69)  0.007 
Lpa (mg/dl)  19.0 (10.0-43.0)  28.0 (12.6-48.6)  0.011  22.0 (14.0-49.1)  30.60 (8.29-51.55)  0.403 
Apo A (mg/dl)  118.5 ± 18.5  114.1 ± 18.0  0.052  118.3 ± 22.4  109.8 ± 17.4  0.060 
Apo B (mg/dl)   75.9 ± 16.0  73.8 ± 17.2   0.498  79.8 ± 14.7  72.9 ± 14.1  0.013 
Chol/HDLc  3.68 (3.17-4.16)  3.60 (3.10-4.50)  0.808  3.91 (3.34-4.24)  3.50 (3.05-4.20)  0.416 
Apo A/Apo B   1.62 ± 0.40   1.60 ± 0.33  0.780  1.54 ± 0.44  1.55 ± 0.37   0.803 
Glucose metabolism 
Glucose (mmol/l)  5.00 (4.83-5.22)  4.80 (4.50-5.10)  0.014  5.00 (4.64 - 5.28)  4.57 (4.04-4.98)  0.002 
Insulin (mmol/l)  12.70 (9.50-15.70)  11.40 (9.54-16.60)  0.395  14.40 (11.60 - 17.80)  10.90 (7.6-14.38)  0.015 
HOMA  2.80 (2.14-3.56)  2.33 (1.82-3.31)  0.255  3.01 (2.41 - 4.24)  1.98 (1.51-2.89)  0.007 
Inflammatoy markers 
Adiponectin (mg/l)  8.58 (5.56-11.66)  6.04 (4.74-9.13)  0.004  9.28 (7.37 - 15.02)  10.17 (6.63-14.22)  0.675 
CRP (mg/l)  1.61 (0.82-4.62)  1.67 (0.78-4.12)  0.402  0.94 (0.43 - 2.02)  1.07 (0.54-2.38)  0.213 
 
      
Fig. (1). Associations between change in body mass index (BMI) over the studied period (one year of follow-up) and BMI and insulin 
resistance  index  (Homeostasis  model  assessment;  HOMA)  values  presented  by  participants  at  baseline.  Spearman’s  rank  correlation 
coefficient values are shown. 
exercise) and an objective measure (BMI z-sc reduction) was 
used to observe which children achieved the objective after 
one year of follow-up. We observed that 17 patients (28.3%) 
presented a significant reduction in BMI z-sc (0.3 or more 
( BMI   -0.3)) over the studied period and that changes in 
BMI over the studied period were independently associated 
with BMI values presented at baseline. It seems that patients 
with higher BMI experience a greater relative reduction in 
their BMI (Fig. 1). Also, the correlation between HOMA in 
the beginning of the study and relative BMI reduction points 
to  a  predisposition  for  children  who  are  more  insulin 
resistant  to  lose  more  weight.  These  associations  can  be 
related to a change in body physiology towards weight loss.  
  In  our  longitudinal  study,  children  did  not  obey  to  a 
restricted  physical  exercise  program  or  a  food  intake 
programme. Also, it was not controlled the initial CRF of our 
population.  Thus,  it  is  impossible  to  know  the  possible 
impact of CRF in BMI z-sc reduction. It is true that the lack 
of standardisation on plans on intervention may mitigate the 
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interpretation of the results that we observed. On the other 
hand,  the  counseling  to  improve  lifestyle  habits  may  be  a 
“more natural” approach, and is useful in clinical practice, as 
participants  can  directly  observe  the  real  benefits  of 
changing their lifestyle habits. Furthermore, the reduction in 
BMI-zc that we observed is likely to express a real change in 
lifestyle habits. 
  It  was  shown  that  3  months  of  moderate  lifestyle 
intervention (45 min of physical activity 3 times per week) in 
obese adolescents seems to attenuate the inflammatory state 
associated  with  obesity,  as  observed  by  a  reduction  in 
elevated circulating concentrations of CRP, fibrinogen and 
IL-6, non-traditional risk factors for CVD [12, 14]. Reinehr 
et al., by evaluating 16 [14] and 10 [13] obese children who 
lost weight over a 1-year period, found a significant decrease 
in CRP but no significant changes in TNF-alpha levels. In 
the  studies  performed  by  Reinehr  et  al.,  obese  children 
participated in a 1-year obesity intervention program and the 
cut-off value used for BMI z-sc reduction was 0.5. As we 
used a smaller cut-off value (0.3), this may explain why we 
did not observe significant changes in CRP levels. Indeed, 
CRP shows a positive association with BMI, and our cut-off 
value may be insufficient to observe clear improvements in 
CRP.  Even  thus,  it  is  important  to  emphasize  that  in  our 
study, involving a larger number of participants, 64.3% of 
the patients that reduced their BMI z-sc presented a decrease 
in circulating CRP levels, in contrast with the group without 
change of BMI z-sc (47.6%). Furthermore, we were able to 
demonstrate  that  smaller  reductions  in  BMI  z-sc  are 
associated with significant improvements in lipid profile and 
in  insulin  resistance  index  HOMA.  Previous  studies 
suggested that the improvement of insulin sensitivity and CV 
risk  factors  in  obese  children  only  occurs  if  BMI  z-sc 
decreases by at least 0.5 over a 1-year period [21], but our 
data  suggests  that  such  improvements  may  be  observable 
with  smaller  reductions  in  BMI-zc.  Again,  our  results  are 
probably explained by the fact that the reductions that we 
observed in BMI z-sc are likely to express a continuous daily 
motivation  in  changing  lifestyle  habits.  Nevertheless, 
although there was no change in HDLc, the lower values of 
HOMA together with the reduction in TG seen in the group 
that  reached  the  cut-off  values  leads  to  the  probable 
influence of concomitant changes in diet and in the levels of 
physical  exercise  in  this  group  to  be  linked  with  the 
improvement seen in the global CV risk profile. 
  The  improvement  in  insulin  sensitivity  with  BMI  z-sc 
reduction observed in our study is of particular importance, 
as  insulin  resistance  represents  a  major  underlying 
abnormality driving CVD [22]. It is important to emphasize 
that insulin resistance associates with increased TG and that 
one of the most striking findings in the longitudinal analysis 
of  the  present  study  was  the  reduction  in  TG  levels. 
Although hypercholesterolemia is a major risk factor for the 
initiation  and  progression  of  atherosclerosis  [23], 
hypertriglyceridemia  and  elevated  levels  of  triglyceride 
(TG)-rich  lipoproteins  have  recently  re-emerged  as  risk 
factors  for  atherosclerosis  [24].  TG-rich  particles  may 
directly  damage  the  endothelium  principally  via  oxidative 
mechanisms.  Also,  an  important  consequence  of 
hypertriglyceridemia,  relating  to  increased  atherosclerotic 
risk, is a shift in the spectrum of LDL subfractions towards 
smaller,  denser  species,  which  are  believed  to  be  more 
atherogenic [25]. Moreover, raised TG levels are frequently 
associated with reduced HDL levels. In our study, we only 
observed a slight (non-significant) increase in HDLc levels, 
which seems to have a protective role in the development of 
atherosclerosis  [26-28].  Reinehr  et  al.  observed  a  trend  to 
increase HDLc levels in patients who achieved a substantial 
BMI z-sc reduction [14]. 
  Plasma Lp(a) levels are known to be mainly genetically 
determined [29, 30]. However, it appears that plasma Lp(a) 
concentration increases with age. In our study, Lp(a) levels 
were similar betweens controls and obese individuals but, in 
the  longitudinal  study  an  increase  in  this  lipoprotein  was 
observed  (Table  4).  In  fact,  this  increase  achieved 
statistically significance in the group without a substantial 
reduction in BMI z-sc. Thus, our data is in agreement with 
the idea that ageing elevates plasma Lp(a) concentration, and 
that  this  increment  might  be  modulated  be  lifestyle 
modifications. 
  Adiponectin is an adipocytokine that has been noted as 
an  important  antiantherogenic,  antidiabetic  and  as  an  anti-
inflammatory  protein  [31].  Adiponectin  seems  to  be 
inversely  related  to  systolic  blood  pressure,  waist 
circumference,  triglycerides,  and  2-hour  glucose  levels, 
while powsitively related to HDL [32]. These associations 
are  in  agreement  with  the  results  obtained  in  our  cross-
sectional study. However, and although it was suggested that 
adolescent obesity is associated with low plasma adiponectin 
levels [33], we were unable to find statistically significant 
differences in plasma levels of adiponectin between obese 
children and controls. This may be explained by the fact that 
we  defined  controls  as  having  a  BMI  lower  than  the  85
th 
percentile adjusted for sex and age, in contrast with other 
work  where  control  group  was  defined  as  a  group  of 
adolescents  who  had  a  BMI  between  the  50
th  and  75
th 
percentiles [33].  
  Regarding  our  longitudinal  study,  it  is  important  to 
highlight  that  adiponectin  levels  decreased  significantly  in 
the  group  without  BMI  z-sc  reduction,  in  contrast  with  a 
moderate  (non-significant)  increase  in  the  group  that 
presented  a  significant  decrease  in  BMI  z-sc.  It  was 
previously reported that a significant weight loss in children, 
defined as BMI z-sc reduction of 0.5 or more, is associated 
with a significant increase in adiponectin [34]. Considering 
the protective effects of adiponectin, it seems reasonable to 
hypothesize  that  the  increase  in  adiponectin  is  likely  to 
explain, at least in part, some of modifications in the lipid 
profile (namely the reduction in triglycerides) and in glucose 
metabolism associated with BMI z-sc reduction. 
  The  concern  with  childhood  obesity  must  begin  in 
overweight children and not only in severe obese children as 
it is easier to intervene in an early phase. Besides, there are 
studies that point that the majority of the diseases appear in 
individuals with moderated elevated risk factors [35].  
  Further studies involving a standardized physical activity 
and diet programs together with the assessment of important 
variables as CRF, at baseline and through the study period, 
could  help  to  better  understand  the  process  involved  in 
weight loss differences found among children and, also, the 
relation between the changes in adiposity and variations in 
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  In  summary,  our  data  demonstrates  that  lifestyle 
modifications  in  obese  children  and  adolescents,  even 
associated with small reductions in BMI z-sc, improve the 
CV risk profile, namely lipid profile and insulin resistance. 
This  may  be  important  in  motivating  patients  as  health 
changes  can  appear  earlier  than  the  esthetical  ones. 
Furthermore,  patients  with  higher  BMI  and/or  insulin 
resistance seem to experience a greater relative reduction in 
their  BMI  after  lifestyle  improvements,  probably  due  to  a 
physiologic adaptation favoring weight loss.  
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